unbranded biosimilar

Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar

Boehringer Ingelheim Adopts Dual-Pricing Strategy with Launch of Unbranded Humira Biosimilar

Anika Sharma

Boehringer Ingelheim, the company that recently introduced the first interchangeable biosimilar to AbbVie’s blockbuster drug Humira, is now embracing a ...